Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 296

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis

Open access
Howard, James F., Bril, Vera, Burns, Ted M., Mantegazza, Renato, Bilinska, Malgorzata, Szczudlik, Andrzej, Beydoun, Said, Garrido, Francisco Javier Rodriguez De Rivera, Piehl, Fredrik, Rottoli, Mariarosa, Van Damme, Philip, Vu, Tuan, Evoli, Amelia, Freimer, Miriam, Mozaffar, Tahseen, Ward, E. Sally, Dreier, Torsten, Ulrichts, Peter, Verschueren, Katrien, Guglietta, Antonio, de Haard, Hans, Leupin, Nicolas, Verschuuren, Jan J.G.M., on behalf of the Efgartigimod MG Study Group, on behalf of the Efgartigimod MG Study Group, Claeys, Kristl, Mathew, Veena, Sgarzi, Manlio, Diez Tejedor, Exuperio, Harvey, Brittany Leigh, Farias, Jerrica, Frangiomore, Rita, Heintsman, Sarah, de Meel, Robert, Chopra, Manisha, Emilio Alboini, Paolo, Genge, Angela · 2019 · Neurology

Abstract

OBJECTIVE: To investigate safety and explore efficacy of efgartigimod (ARGX-113), an anti-neonatal Fc receptor immunoglobulin G1 Fc fragment, in patients with generalized myasthenia gravis (gMG) with a history of anti-acetylcholine receptor (AChR) autoantibodies, who were on stable standard-of-care myasthenia gravis (MG) treatment. METHODS: A phase 2, exploratory, randomized, double-blind, placebo-controlled, 15-center study is described. Eligible patients were randomly assigned (1:1) to receive 4 doses over a 3-week period of either 10 mg/kg IV efgartigimod or matched placebo combined with their standard-of-care therapy. Primary endpoints were safety and tolerability. Secondary endpoints included efficacy (change from baseline to week 11 of Myasthenia Gravis Activities of Daily Living, Quantitative Myasthenia Gravis, and Myasthenia Gravis Composite disease severity scores, and of the revised 15-item Myasthenia Gravis Quality of Life scale), pharmacokinetics, pharmacodynamics, and immunogenicity. RESULTS: Of the 35 screened patients, 24 were enrolled and randomized: 12 received efgartigimod and 12 placebo. Efgartigimod was well-tolerated in all patients, with no serious or severe adverse events reported, no relevant changes in vital signs or ECG findings observed, and no difference in adverse events between efgartigimod and placebo treatment. All patients treated with efgartigimod showed a rapid decrease in total immunoglobulin G (IgG) and anti-AChR autoantibody levels, and assessment using all 4 efficacy scales consistently demonstrated that 75% showed a rapid and long-lasting disease improvement. CONCLUSIONS: Efgartigimod was safe and well-tolerated. The correlation between reduction of levels of pathogenic IgG autoantibodies and disease improvement suggests that reducing pathogenic autoantibodies with efgartigimod may offer an innovative approach to treat MG. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that efgartigimod is safe and well-tolerated in patients with gMG.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000007600

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 20 references

Cited by

See all 296

Metadata

Authors
Howard, J. F., Bril, V., Burns, T. M., Mantegazza, R., Bilinska, M., Szczudlik, A., Beydoun, S., Garrido, F. J. R. D. R., Piehl, F., Rottoli, M., Van Damme, P., Vu, T., Evoli, A., Freimer, M., Mozaffar, T., Ward, E. S., Dreier, T., Ulrichts, P., Verschueren, K., Guglietta, A., de Haard, H., Leupin, N., Verschuuren, J. J. G. M., on behalf of the Efgartigimod MG Study Group, on behalf of the Efgartigimod MG Study Group, Claeys, K., Mathew, V., Sgarzi, M., Diez Tejedor, E., Harvey, B. L., Farias, J., Frangiomore, R., Heintsman, S., de Meel, R., Chopra, M., Emilio Alboini, P., & Genge, A.
Venue
Neurology
Published
2019-06-04
Volume
92
Issue
23
Pages
e2661-e2673
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2944937742
Cited by
296
References
20
FWCI
18.57
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. https://app.cochat.ai/papers/10.1212/wnl.0000000000007600
The paper
Howard, J. F., Bril, V., Burns, T. M., Mantegazza, R., Bilinska, M., Szczudlik, A., Beydoun, S., Garrido, F. J. R. D. R., Piehl, F., Rottoli, M., Van Damme, P., Vu, T., Evoli, A., Freimer, M., Mozaffar, T., Ward, E. S., Dreier, T., Ulrichts, P., Verschueren, K., . . . Genge, A. (2019). Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology. https://doi.org/10.1212/wnl.0000000000007600

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.